Business Context and Reporting Period
Compugen Ltd. (NASDAQ: CGEN), a biotechnology company focused on predictive discovery of therapeutics and diagnostic biomarkers, reported financial results for the second quarter ended June 30, 2007. The filing is a Form 6-K submitted on August 2, 2007. The company's primary commercialization strategy involves out-licensing and joint development agreements.
Key Financial Metrics
| Metric | Q2 2007 | Q2 2006 | 6 Months 2007 | 6 Months 2006 |
|---|---|---|---|---|
| Revenues | $0 | $5,000 | $0 | $205,000 |
| Net Loss (Continuing Ops) | $(2.7M) | $(3.3M) | $(5.6M) | $(6.0M) |
| Net Loss (Total) | $(3.2M) | $(3.6M) | $(6.3M) | $(6.7M) |
| Loss Per Share (Total) | $(0.11) | $(0.13) | $(0.22) | $(0.24) |
| R&D Expenses (Net of Grants) | $2.0M | $2.6M | $4.1M | $4.7M |
| Cash and Equivalents | $20.8M | N/A | N/A | N/A |
Liquidity and Debt: As of June 30, 2007, the company held $20.8 million in cash, cash equivalents, deposits, and marketable securities. This represents a decrease of $5.6 million from December 31, 2006. The filing does not disclose specific long-term debt obligations, though accrued severance pay of $1.5 million is listed under long-term liabilities.
Material Changes
- Revenue Decline: Revenues were insignificant in Q2 2007 ($0) compared to $5,000 in Q2 2006. For the six-month period, revenues dropped from $205,000 in 2006 to $0 in 2007.
- Reduced Losses: The net loss from continuing operations narrowed by approximately 18% in Q2 2007 compared to the prior year, driven primarily by a reduction in Research and Development (R&D) expenses.
- R&D Efficiency: Gross R&D expenses decreased from $2.7 million in Q2 2006 to $2.3 million in Q2 2007. Additionally, governmental grants increased significantly from $105,000 to $293,000, further reducing net R&D costs.
- Affiliate Status: Evogene, an agricultural biotechnology affiliate, completed an IPO on the Tel Aviv Stock Exchange. Keddem, a small molecule drug discovery affiliate, is limiting activities to corporate development and IP protection pending third-party funding.
Outlook, Risks, and Management Commentary
Management Commentary: CEO Alex Kotzer and Chairman Martin Gerstel highlighted significant progress in product candidate development and the creation of a new proprietary discovery engine. This engine is designed to identify existing drug molecules with unknown therapeutic indications using computational biology, followed by experimental validation. Management emphasized the efficiency of this hypothesis-driven process compared to random high-throughput screening.
Guidance: The filing does not provide specific numerical financial guidance for future periods. Management reiterated that current revenues are expected to remain insignificant.
Risks and Contingencies:
- Discontinued Operations: Keddem's assets are classified as "Assets related to discontinued operations" due to uncertainty regarding future financing.
- Forward-Looking Risks: Risks include changes in collaborator relationships, competitive products, technological changes, and the ability to obtain and retain customers.
- Accounting Changes: Following Evogene's IPO, Compugen's investment is now recorded at market price for unrestricted shares, impacting balance sheet valuation.
Investor Verification Checklist
- Verify the sustainability of the $293,000 in governmental grants received in Q2 2007 and their impact on future R&D burn rates.
- Confirm the timeline and probability of third-party funding for the Keddem affiliate to assess the risk of further write-downs in discontinued operations.
- Review the specific milestones and revenue-sharing terms of any new licensing agreements mentioned in the "negotiations" phase.
- Monitor the cash burn rate, noting the $5.6 million decrease in liquidity over the first six months of 2007.
- Validate the valuation methodology for the $124,000 investment in Evogene recorded on the balance sheet post-IPO.